$MRNS News Article - Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD) https://marketwirenews.com/news-releases/mari...28319.html
Marinus Pharmaceuticals Inc. (MRNS) Stock Research Links
My Twitter: WhyteStocks